Last reviewed · How we verify
HDT-301
At a glance
| Generic name | HDT-301 |
|---|---|
| Sponsor | HDT Bio |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein (PHASE1)
- Study to Assess Safety, Reactogenicity and Immunogenicity of the VACCINE RNA MCTI CIMATEC HDT (HDT-301) Vaccine Against COVID-19 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HDT-301 CI brief — competitive landscape report
- HDT-301 updates RSS · CI watch RSS
- HDT Bio portfolio CI